Recent studies indicate that the hyperactivation of the PD-1/PD-L1 axis in Alzheimer’s disease (AD) brain has an influence on disease pathophysiology. With this in mind, researchers from Sungkyunkwan University evaluated INR-301, a novel superior blood-brain barrier (BBB)-penetrating anti-PD-L1 antibody, in an AD model.